Blockchain believers have delivered little more than hype, mostly failing to get it deployed outside the cryptocurrency space where the technology was developed. But a little-noticed U.S. law could change that, bringing the ledger system to the pharmaceutical business.

Some of the world’s biggest companies are drawing up plans for the unplannable: a March divorce between Britain and the European Union, in which even some basic parameters have yet to be hammered out.

European companies aren’t alone in their Brexit pain. Pfizer, the U.S.-based drug behemoth, says its costs for dealing with the upcoming split will reach $100m.

As any supply chain professional knows, sourcing is a critical element of effective procurement.

Low-slung industrial developments are rising along Avenue 48 in Coachella, California, a dusty stretch at the edge of relentless desert 140 miles from the Pacific Coast that’s becoming a hub for cannabis producers.

The 35 must-watch technologies represented on the Gartner Inc. Hype Cycle for Emerging Technologies, 2018 revealed five distinct emerging technology trends that will blur the lines between humans and machines.

Blockchain technology has emerged as a solution to building stronger, safer and more resilient cold supply chains.